7044-35-1
7044-35-1
Chemical Structure
Asperilin
Synonym(s): NSC 85238
- CAS No.: 7044-35-1
- Formula:C15H20O3
- Molecular Weight:248.32
InChIKey: GAUPAOVCTWBVKC-WPLOAARJSA-N
SMILES: C[C@]12[C@@](C(CC[C@H]2O)=C)([H])C[C@@]3([H])[C@@](OC(C3=C)=O)([H])C1
Biological Activity: Asperilin (NSC 85238) is an orally active sesquiterpene lactone. Asperilin depletes hepatic glutathione in vivo, induces hepatic microsomal lipid peroxidation, elevates glutathione peroxidase activity, and mildly increases plasma AST and ALT. Asperilin scavenges hydroxyl radicals. Asperilin shows anticancer activity against melanoma[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Asperilin | Asperilin (NSC 85238) is an orally active sesquiterpene lactone. Asperilin depletes hepatic glutathione in vivo, induces hepatic microsomal lipid peroxidation, elevates glutathione peroxidase activity, and mildly increases plasma AST and ALT. Asperilin scavenges hydroxyl radicals. Asperilin shows anticancer activity against melanoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zárybnický T, et al. Hepatotoxicity of monoterpenes and sesquiterpenes. Archives of toxicology. 2018 Jan;92(1):1-13.
- [2]. Wajs-Bonikowska A, et al. Bioprospecting of the Telekia speciosa: Uncovering the composition and biological properties of its essential oils[J]. Applied Sciences, 2023, 13(9): 5674.
- [3]. He S, et al. Herb-Induced Liver Injury: Phylogenetic Relationship, Structure-Toxicity Relationship, and Herb-Ingredient Network Analysis. International journal of molecular sciences. 2019 Jul 25;20(15):3633.
- [4]. Jodynis-Liebert, et al. Effect of several sesquiterpene lactones on lipid peroxidation and glutathione level. Planta Med. 1999 May;65(4):320-4. [Content Brief]
- [5]. Wang GW, et al. Inula sesquiterpenoids: structural diversity, cytotoxicity and anti-tumor activity. Expert opinion on investigational drugs. 2014 Mar;23(3):317-45.
